UBS Oncology Impact Fund L.P. Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for UBS Oncology Impact Fund L.P..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of UBS Oncology Impact Fund L.P.. UBS Oncology Impact Fund L.P. is 10% Owner in Oncorus, Inc. ($ONCR) and 10% Owner in Harpoon Therapeutics, Inc. ($HARP) and 10% Owner in TCR2 THERAPEUTICS INC. ($TCRR) and 10% Owner in Cullinan Management, Inc. ($CGEM).
Latest Insider Trading Transactions of UBS Oncology Impact Fund L.P.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, CGEM, HARP, ONCR, TCRR
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 14 2021 | CGEM | Cullinan Managemen ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 649,030 | 0 | 0 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 2,276,692 | 0 | 0 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 3,551,640 | 0 | 0 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,136,525 | 0 | 0 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | P | 21.00 | 300,000 | 6,300,000 | 7,913,887 | 7.6 M to 7.9 M (+3.94 %) |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 649,030 | 0 | 7,613,887 | 7 M to 7.6 M (+9.32 %) |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 2,276,692 | 0 | 6,964,857 | 4.7 M to 7 M (+48.56 %) |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 3,551,640 | 0 | 4,688,165 | 1.1 M to 4.7 M (+312.50 %) |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 1,136,525 | 0 | 1,136,525 | 0 to 1.1 M |
| Oct 08 2020 | ONCR | Oncorus, Inc. | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 700,453 | 0 | 0 | |
| Oct 08 2020 | ONCR | Oncorus, Inc. | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,525,348 | 0 | 0 | |
| Oct 08 2020 | ONCR | Oncorus, Inc. | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | P | 15.00 | 151,224 | 2,268,360 | 2,377,025 | 2.2 M to 2.4 M (+6.79 %) |
| Oct 08 2020 | ONCR | Oncorus, Inc. | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 700,453 | 0 | 2,225,801 | 1.5 M to 2.2 M (+45.92 %) |
| Oct 08 2020 | ONCR | Oncorus, Inc. | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 1,525,348 | 0 | 1,525,348 | 0 to 1.5 M |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,750,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 15,000,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | P | 15.00 | 666,667 | 10,000,005 | 3,370,982 | 2.7 M to 3.4 M (+24.65 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 282,540 | 0 | 2,704,315 | 2.4 M to 2.7 M (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 2,421,775 | 0 | 2,421,775 | 0 to 2.4 M |
| Feb 14 2019 | HARP | Harpoon Therapeuti ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | X | 0.05 | 50,838 | 2,501 | 0 | |
| Feb 14 2019 | HARP | Harpoon Therapeuti ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | X | 0.05 | 76,258 | 3,752 | 0 | |
| Feb 14 2019 | HARP | Harpoon Therapeuti ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 417,853 | 0 | 0 | |
| Feb 14 2019 | HARP | Harpoon Therapeuti ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,578,755 | 0 | 0 | |
| Feb 14 2019 | HARP | Harpoon Therapeuti ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,525,165 | 0 | 0 | |
| Feb 14 2019 | HARP | Harpoon Therapeuti ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | P | 14.00 | 250,000 | 3,500,000 | 3,898,422 | 3.6 M to 3.9 M (+6.85 %) |
| Feb 14 2019 | HARP | Harpoon Therapeuti ... | UBS Oncology Impact Fund L.P. | 10% Owner | Sell | S | 14.00 | 447 | 6,258 | 3,648,422 | 3.6 M to 3.6 M (-0.01 %) |
| Feb 14 2019 | HARP | Harpoon Therapeuti ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | X | 0.05 | 127,096 | 6,253 | 3,648,869 | 3.5 M to 3.6 M (+3.61 %) |
| Feb 14 2019 | HARP | Harpoon Therapeuti ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 417,853 | 0 | 3,521,773 | 3.1 M to 3.5 M (+13.46 %) |
| Feb 14 2019 | HARP | Harpoon Therapeuti ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 1,578,755 | 0 | 3,103,920 | 1.5 M to 3.1 M (+103.51 %) |
| Feb 14 2019 | HARP | Harpoon Therapeuti ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 1,525,165 | 0 | 1,525,165 | 0 to 1.5 M |
Page: 1